Manufacturing of critical drug for radiological & nuclear emergencies gets DCGI approval

14 March 2023 | News

Prussian blue insoluble formulations developed by the industry on a DRDO technology

image credit- shutterstock

image credit- shutterstock

Manufacturing and marketing licenses for the commercial use of Prussian blue insoluble formulations, developed under the Technology Development Fund (TDF) scheme, have been granted to Scott-Edil Pharmacia, Baddi, Himachal Pradesh and Skanttr Lifescience LLP, Ahmedabad, Gujarat by Drugs Controller General of India (DCGI).

The drug has been developed by the industry based on the technology of Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi, a laboratory of Defence Research & Development Organisation (DRDO).

The drug will be available under the trade name of Pru-DecorpT and PruDecorp-MG. The formulations are used for decontamination of Cesium & Thallium and its Active Pharmaceutical Ingredient (API). It is one of the critical medicines listed by the World Health Organisation (WHO) for radiological and nuclear emergencies.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account